U.S. Multiomics Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Consumables), By Type (Single-cell, Bulk), By Platform, By Application, By End Use, And Segment Forecasts, 2025

The U.S. multiomics market size was estimated at USD 1.18 billion in 2024 and is projected to reach USD 4.36 billion by 2033, growing at a CAGR of 15.58% from 2025 to 2033. This significant growth is driven by increasing demand for personalized medicine, the integration of artificial intelligence and machine learning in biological data interpretation, and the growing need for comprehensive disease profiling. Moreover, rising investments in research and development by both the government and private sectors and expanding applications in drug discovery, diagnostics, and precision healthcare are expected to propel market growth further over the forecast period.

Technological Innovations

The rapid pace of technological innovation across omics platforms and analytical tools is the key driver in the U.S. multiomics industry. Breakthroughs in high-throughput sequencing technologies, such as next-generation sequencing (NGS), have dramatically increased the speed and depth of genomic and transcriptomic data generation while reducing the cost per sample. Similarly, advancements in mass spectrometry, chromatography, and imaging technologies have significantly improved the resolution and sensitivity of proteomics and metabolomics studies. These innovations enable researchers to obtain a more detailed and accurate view of complex biological processes, essential for applications in disease research, drug discovery, and precision diagnostics.

The evolution of powerful computational tools, cloud-based platforms, and AI-driven analytics has revolutionized how multiomics data is processed, integrated, and interpreted. These technologies allow for the seamless analysis of large-scale, multi-layered datasets, reducing bottlenecks in data handling and accelerating insights. As a result, multiomics workflows are becoming more automated, scalable, and cost-effective, making them increasingly accessible to large pharmaceutical companies and smaller biotech firms, academic institutions, and clinical laboratories. The convergence of these technological advancements is not only expanding the application of multiomics across new disease areas. Still, it is also helping to democratize access to multiomics research, thereby accelerating the market's growth in the U.S.

U.S. Multiomics Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. multiomics market report based on product & service, type, platform, application, and end use:

Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
Products
- Instruments
- Consumables
- Software
Services
Type Outlook (Revenue, USD Million, 2021 - 2033)
Single-cell Multiomics
Bulk Multiomics
Platform Outlook (Revenue, USD Million, 2021 - 2033)
Genomics
Transcriptomics
Proteomics
Metabolomics
Integrated Omics Platforms
Application Outlook (Revenue, USD Million, 2021 - 2033)
Cell Biology
Oncology
Neurology
Immunology
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Academic and Research Institutes
Pharmaceutical & Biotechnology Companies
Others

Product Code: GVR-4-68040-282-8

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
- 1.2.1. Product & Service
- 1.2.2. Type
- 1.2.3. Platform
- 1.2.4. Application
- 1.2.5. End Use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
- 1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Technological Innovation
  - 3.2.1.2. Advancements in precision medicine
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Data integration and analytical complexity
  - 3.2.2.2. High cost of multiomics technologies and workflows
3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis

Chapter 4. U.S. Multiomics Market: Product & Service Business Analysis

4.1. Segment Dashboard
4.2. U.S. Multiomics Market Product & Service Movement Analysis
4.3. U.S. Multiomics Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
4.4. Product
- 4.4.1. Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Instruments
  - 4.4.2.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Consumables
  - 4.4.3.1. Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.4. Software
  - 4.4.4.1. Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Services
- 4.5.1. Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Multiomics Market: Type Business Analysis

5.1. Segment Dashboard
5.2. U.S. Multiomics Market Type Movement Analysis
5.3. U.S. Multiomics Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
5.4. Single-cell Multiomics
- 5.4.1. Single-cell Multiomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Bulk Multiomics
- 5.5.1. Bulk. Multiomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Multiomics Market: Platform Business Analysis

6.1. Segment Dashboard
6.2. U.S. Multiomics Market Platform Movement Analysis
6.3. U.S. Multiomics Market Size & Trend Analysis, by Platform, 2021 to 2033 (USD Million)
6.4. Genomics
- 6.4.1. Genomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Transcriptomics
- 6.5.1. Transcriptomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Proteomics
- 6.6.1. Proteomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Metabolomics
- 6.7.1. Metabolomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Integrated Omics Platforms
- 6.8.1. Integrated Omics Platforms Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Multiomics Market: Application Business Analysis

7.1. Segment Dashboard
7.2. U.S. Multiomics Market Application Movement Analysis
7.3. U.S. Multiomics Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
7.4. Cell Biology
- 7.4.1. Cell Biology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Oncology
- 7.5.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Neurology
- 7.6.1. Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Immunology
- 7.7.1. Immunology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Multiomics Market: End Use Business Analysis

8.1. Segment Dashboard
8.2. U.S. Multiomics Market End Use Movement Analysis
8.3. U.S. Multiomics Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
8.4. Academic and Research Institutes
- 8.4.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Pharmaceutical & Biotechnology Companies
- 8.5.1. Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Others
- 8.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Participant Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Participant's Overview
- 9.4.1. BD
  - 9.4.1.1. Overview
  - 9.4.1.2. Financial Performance
  - 9.4.1.3. Product Benchmarking
  - 9.4.1.4. Strategic Initiatives
- 9.4.2. Thermo Fisher Scientific Inc.
  - 9.4.2.1. Overview
  - 9.4.2.2. Financial Performance
  - 9.4.2.3. Product Benchmarking
  - 9.4.2.4. Strategic Initiatives
- 9.4.3. Illumina, Inc
  - 9.4.3.1. Overview
  - 9.4.3.2. Financial Performance
  - 9.4.3.3. Product Benchmarking
  - 9.4.3.4. Strategic Initiatives
- 9.4.4. Danaher (Beckman Coulter)
  - 9.4.4.1. Overview
  - 9.4.4.2. Financial Performance
  - 9.4.4.3. Product Benchmarking
  - 9.4.4.4. Strategic Initiatives
- 9.4.5. PerkinElmer Inc.
  - 9.4.5.1. Overview
  - 9.4.5.2. Financial Performance
  - 9.4.5.3. Product Benchmarking
  - 9.4.5.4. Strategic Initiatives
- 9.4.6. Shimadzu Corporation
  - 9.4.6.1. Overview
  - 9.4.6.2. Financial Performance
  - 9.4.6.3. Product Benchmarking
  - 9.4.6.4. Strategic Initiatives
- 9.4.7. Bruker
  - 9.4.7.1. Overview
  - 9.4.7.2. Financial Performance
  - 9.4.7.3. Product Benchmarking
  - 9.4.7.4. Strategic Initiatives
- 9.4.8. QIAGEN
  - 9.4.8.1. Overview
  - 9.4.8.2. Financial Performance
  - 9.4.8.3. Product Benchmarking
  - 9.4.8.4. Strategic Initiatives
- 9.4.9. Agilent Technologies, Inc.
  - 9.4.9.1. Overview
  - 9.4.9.2. Financial Performance
  - 9.4.9.3. Product Benchmarking
  - 9.4.9.4. Strategic Initiatives
- 9.4.10. BGI Genomics
  - 9.4.10.1. Overview
  - 9.4.10.2. Financial Performance
  - 9.4.10.3. Product Benchmarking
  - 9.4.10.4. Strategic Initiatives

Product Code: GVR-4-68040-282-8

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. multiomics market, by product & service, 2021 - 2033 (USD Million)
Table 4 U.S. multiomics market, by type, 2021 - 2033 (USD Million)
Table 5 U.S. multiomics market, by platform, 2021 - 2033 (USD Million)
Table 6 U.S. multiomics market, by application, 2021 - 2033 (USD Million)
Table 7 U.S. multiomics market, by end use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Multiomics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market outlook
Fig. 10 Segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Parent market outlook
Fig. 13 U.S. multiomics market driver analysis
Fig. 14 U.S. multiomics market restraint analysis
Fig. 15 U.S. multiomics market: Porter's analysis
Fig. 16 U.S. multiomics market: PESTEL analysis
Fig. 17 U.S. multiomics market: Product & service outlook and key takeaways
Fig. 18 U.S. multiomics market: Product & service market share analysis, 2024 - 2033
Fig. 19 U.S. multiomics by products market, 2021 - 2033 (USD Million)
Fig. 20 U.S. multiomics by instruments market, 2021 - 2033 (USD Million)
Fig. 21 U.S. multiomics by consumables market, 2021 - 2033 (USD Million)
Fig. 22 U.S. multiomics by software market, 2021 - 2033 (USD Million)
Fig. 23 U.S. multiomics by services market, 2021 - 2033 (USD Million)
Fig. 24 U.S. Multiomics market: Type outlook and key takeaways
Fig. 25 U.S. Multiomics market: Type market share analysis, 2024 - 2033
Fig. 26 U.S. multiomics by single-cell multiomics market, 2021 - 2033 (USD Million)
Fig. 27 U.S. multiomics by bulk multiomics market, 2021 - 2033 (USD Million)
Fig. 28 U.S. Multiomics market: Platform outlook and key takeaways
Fig. 29 U.S. Multiomics market: Platform market share analysis, 2024 - 2033
Fig. 30 U.S. multiomics by genomics market, 2021 - 2033 (USD Million)
Fig. 31 U.S. multiomics by transcriptomics market, 2021 - 2033 (USD Million)
Fig. 32 U.S. multiomics by proteomics market, 2021 - 2033 (USD Million)
Fig. 33 U.S. multiomics by metabolomics market, 2021 - 2033 (USD Million)
Fig. 34 U.S. multiomics by integrated omics platforms market, 2021 - 2033 (USD Million)
Fig. 35 U.S. Multiomics market: Application outlook and key takeaways
Fig. 36 U.S. Multiomics market: Application market share analysis, 2024 - 2033
Fig. 37 U.S. multiomics by cell biology market, 2021 - 2033 (USD Million)
Fig. 38 U.S. multiomics by oncology market, 2021 - 2033 (USD Million)
Fig. 39 U.S. multiomics by neurology market, 2021 - 2033 (USD Million)
Fig. 40 U.S. multiomics by immunology market, 2021 - 2033 (USD Million)
Fig. 41 U.S. Multiomics market: End use outlook and key takeaways
Fig. 42 U.S. Multiomics market: End use market share analysis, 2024 - 2033
Fig. 43 U.S. multiomics by academic and research institutes market, 2021 - 2033 (USD Million)
Fig. 44 U.S. multiomics by pharmaceutical & biotechnology companies market, 2021 - 2033 (USD Million)
Fig. 45 U.S. multiomics by others market, 2021 - 2033 (USD Million)
Fig. 46 Key company categorization
Fig. 47 Company market positioning
Fig. 48 Market participant categorization
Fig. 49 Strategy framework

U.S. Multiomics Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Consumables), By Type (Single-cell, Bulk), By Platform, By Application, By End Use, And Segment Forecasts, 2025 - 2033

Description

Table of Contents

List of Tables

U.S. Multiomics Market Summary

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. U.S. Multiomics Market: Product & Service Business Analysis

Chapter 5. U.S. Multiomics Market: Type Business Analysis

Chapter 6. U.S. Multiomics Market: Platform Business Analysis

Chapter 7. U.S. Multiomics Market: Application Business Analysis

Chapter 8. U.S. Multiomics Market: End Use Business Analysis

Chapter 9. Competitive Landscape

List of Tables

List of Figures